MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2023.1259071

Медицинская библиотека · Frontiers in immunology · 2023

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review.

Nakamura Hajime, Shionoya Aika, Arihara Yohei, Hayasaka Naotaka, Kubo Tomohiro, Usami Makoto, Sugita Shintaro, Uhara Hisashi, Takada Kohichi

ОбзорКлинический случайСтатьяПеревод в очереди

Аннотация

Ipilimumab plus nivolumab therapy is approved for patients with unresectable advanced esophageal squamous cell carcinoma (ESCC). Although a combination of immune checkpoint inhibitors (ICIs), compared to conventional chemotherapy, can improve overall survival in patients with advanced ESCC, this increases the incidence of immune-related adverse events (irAEs). Here, we describe an ESCC case that developed pemphigus vulgaris (PV), an extremely rare cutaneous irAE, during ipilimumab plus nivolumab treatment. The patient achieved a partial response to treatment. The PV was successfully managed after the cessation of ipilimumab and the use of a topical steroid. We should thus re-treat ESCC with nivolumab monotherapy. In the era of ICIs as standard cancer therapeutics, diagnostic criteria for blistering diseases need to be established to properly manage patients with cutaneous irAEs.

Для цитирования: Nakamura Hajime, Shionoya Aika, Arihara Yohei, Hayasaka Naotaka, Kubo Tomohiro, Usami Makoto, Sugita Shintaro, Uhara Hisashi, Takada Kohichi. Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review.. Frontiers in immunology. 2023. DOI: 10.3389/fimmu.2023.1259071.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.